Shannon Mooring
Adult Health · Clayton, NCNPI 1669782470
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,406 of the $4,745 with a category attached, or 71.8%. Boehringer Ingelheim accounts for 61.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $3,879 and has fallen 95.8% since, to $162 in 2025. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $91.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Lilly USA, LLC$656
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$441
- E.r. Squibb & Sons, L.L.C.$174
- Alnylam Pharmaceuticals Inc.$128
- Actelion Pharmaceuticals US, Inc.$125
- plus $281 from 6 others
What the payments were for
- Speaking & faculty fees$3,40672%
- Food & beverage$1,33928%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $2,939 |
| Lilly USA, LLC | 2 | $656 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $441 |
| E.r. Squibb & Sons, L.L.C. | 4 | $174 |
| Alnylam Pharmaceuticals Inc. | 1 | $128 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Philips North America LLC | 1 | $78 |
| Kestra Medical Technology Services, Inc. | 1 | $62 |
| AstraZeneca | 3 | $62 |
| Novartis | 2 | $42 |
| Abbott | 1 | $22 |
| Bristol Myers Squibb | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,745 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 549 | $417,909 |
| XareltoRivaroxaban | 71 | $75,248 |
| EntrestoSacubitril/Valsartan | 73 | $64,765 |
| JardianceEmpagliflozin | 41 | $36,153 |
| FarxigaDapagliflozin Propanediol | 19 | $14,122 |
| Dofetilide | 18 | $6,812 |
| Ranolazine ErRanolazine | 51 | $5,328 |
| Metoprolol Succinate | 619 | $5,211 |
| Prasugrel Hcl | 47 | $5,036 |
| Midodrine Hcl | 52 | $4,124 |
| ClopidogrelClopidogrel Bisulfate | 337 | $3,310 |
| Losartan Potassium | 340 | $3,062 |
| Amlodipine Besylate | 525 | $2,444 |
| Nebivolol Hcl | 39 | $2,291 |
| Pantoprazole Sodium | 184 | $2,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $42 | $64,76573 claims |
| Boehringer IngelheimJardiance | $2,939 | $36,15341 claims |
| AstraZenecaFarxiga | $62 | $14,12219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.
Other adult health in Clayton
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
- Chaely MedleyChapel Hill$47K
- Ann ShumDurham$35K
- Amy HopkinsGreenville$31K
- Stephanie YatesDurham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.